Finder R L, Moore P A, Close J M
Department of Anesthesiology, University of Pittsburgh School of Dental Medicine, Pennsylvania 15261, USA.
Anesth Prog. 1995;42(1):11-6.
The addition of a benzodiazepine antagonist to the dental anesthesiologist's armamentarium should provide added safety for conscious sedation using benzodiazepines. A double-blind, placebo-controlled clinical trial of flumazenil, the first available benzodiazepine antagonist, was performed to evaluate its safety and efficacy following conscious sedation induced by diazepam and fentanyl. Flumazenil was found to reverse rapidly much of the central nervous system depression induced by fentanyl and diazepam conscious sedation. Flumazenil appears to be a valuable adjunct for dentists who administer intravenous benzodiazepines for conscious sedation.
在牙科麻醉医生的常用药物中添加苯二氮䓬拮抗剂，可为使用苯二氮䓬类药物进行清醒镇静提供更高的安全性。对首个可用的苯二氮䓬拮抗剂氟马西尼进行了一项双盲、安慰剂对照临床试验，以评估其在由地西泮和芬太尼诱导的清醒镇静后的安全性和有效性。结果发现，氟马西尼能迅速逆转芬太尼和地西泮清醒镇静所引起的大部分中枢神经系统抑制作用。对于使用静脉注射苯二氮䓬类药物进行清醒镇静的牙医而言，氟马西尼似乎是一种有价值的辅助药物。
